announcement ropren pricing updat, page-5

30 September, 2008
Company Announcement
Market Update
The Directors of Solagran Limited are pleased to provide the market with a brief update in
relation to matters discussed at the information evening held on 3 September.
Ropren® Sales and Pricing
Initial sales of Ropren® in countries outside Russia have commenced with prices realised at
or above a baseline level of $3,000 for a standard three month course. Volume sales in
Russia are expected to commence within weeks.
Bioeffectives® Production and Russian Operations
Enhancements to the Tomsk production facility outlined on 3 September have proceeded
according to plan, and the Bioeffective® R (polyprenols) production plan presented by the
Managing Director of SibEX, Mr Alexander Kurganov, is on track.
Formal documents confirming Solagran’s participation in the Tomsk Special Economic Zone
with its many benefits including an attractive concessional tax regime are still expected to be
signed by the Russian Prime Minister in October. However the company has now received
documentation from the SEZ authority that will enable the Russian end of its international
corporate structure to be finalised. Implementation has begun and Solagran’s advisors have
indicated the entire structure should be operational within eight weeks.
Solagran’s Director of Russian Operations, Mr Charles Pellegrino, departed yesterday for
Russia to sign off on the production plan, complete certain formalities in relation to the
corporate structure, and finalise arrangements for Ropren® distribution.
The Directors hope to finalise all remaining matters related to Ropren® distribution in Russia
during Mr Pellegrino’s current trip. They are also confident that both the demand and the
price per course in Russia will match or exceed the levels indicated at the shareholder
meeting on 3 September.
Peter Stedwell
Company Secretary
On behalf of the Board of Directors